DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Divi's Laboratories Limited (DIVISLAB) share price today?

Divi's Laboratories Limited (DIVISLAB) is trading at ₹9,144.5 on the NSE, up 1.27% on the day. Source: DocStoX.

What is the PE ratio of Divi's Laboratories Limited?

Divi's Laboratories Limited has a price-to-earnings (PE) ratio of 94.5 in the Healthcare sector.

What is the market capitalisation of Divi's Laboratories Limited?

Divi's Laboratories Limited has a market capitalisation of approximately ₹2.45 lakh crore.

Is Divi's Laboratories Limited a profitable company?

Divi's Laboratories Limited generates a return on equity of 15.3% with a net profit margin of 24.3%. That is a reasonable return on shareholder capital.

What is the 52-week high and low of DIVISLAB?

Divi's Laboratories Limited (DIVISLAB) has traded between ₹5,647.5 and ₹9,740 over the past 52 weeks, against a current price of ₹9,144.5.

Does Divi's Laboratories Limited pay a dividend?

Yes. Divi's Laboratories Limited currently offers a dividend yield of 0.32%. Dividend payments depend on the board's declaration each year.

Divi's Laboratories Limited

F&O

₹9,144.50▲ +114.50 (+1.27%)

DIVISLAB·NSE·Healthcare

Market Cap

244762.03 Cr

PE Ratio

94.52

Volume

7,78,446

Day High - Low

9248.00 - 8985.50

52W High-Low

9740.00 - 5647.50

₹9,144.50▲ +114.50 (+1.27%)

Market Cap244762.03 Cr

PE Ratio94.52

Volume7,78,446

Day High - Low9248.00 - 8985.50

52W High-Low9740.00 - 5647.50

Divi's Laboratories Limited (DIVISLAB): company summary

The company's business has improved, with annual revenue rising 12.8% and annual net profit growing 17.2%.

Divi's Laboratories Limited (DIVISLAB) is a large-cap Healthcare company valued at ₹2.45 lakh crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Divi's Laboratories Limited last traded at ₹9,144.5, modestly up 1.27% on the day.
Recent developments: On 2026-07-24, the company announced a dividend of ₹30.00 per share, effective from that date. Promoter holding remained at 51.88% as of 2026-09-30. Foreign institutional holding increased by 0.18 percentage points, while domestic institutional holding decreased by 0.21 percentage points in the quarter.
Financial performance: The company's business has improved, with annual revenue rising 12.8% and annual net profit growing 17.2%. The latest quarter saw revenue surge 27.8% and net profit jump 65.5% compared to the same quarter a year earlier. Net profit margin widened to 24.3% from 23.4%, while return on equity remained stable at 15.3%.
Valuation multiples: The stock trades at 94.5 times earnings, a premium to the Healthcare median of 32.0, 14.90 times book value. It yields 0.3%.
Things to watch: The stock is 6.1% below its 52-week high. Domestic institutional holding fell by 0.21 percentage points in the quarter. The company's revenue growth has slowed in recent quarters, with a 5-year CAGR of 8.7% compared to a 3-year CAGR of 10.8%.
Where it stands: The company has delivered strong growth in both revenue and net profit, with the latest quarter showing significant improvement. The stock is trading below its 52-week high, and institutional holdings have shifted slightly. The most recent figure is the latest quarter net profit of ₹902 crore.

Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

5.7/10

Fair

Fair Value

ROE

15.32%

Strong

P/E

94.52x

Expensive

Debt / Equity

0.00

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY NEXT 50NIFTY 100NIFTY 200

Day₹8986

₹9248

52W₹5648

₹9740

DocStoX take

Supported by risk (9.8) and momentum (7.5), but held back by valuation (0.0). Risk looks strong at 9.8, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

5.7

/10

Fair

Quality

Solid

ROE 15.3%

Valuation

Expensive

P/E 94.5×

Growth

Slow

Revenue +8.7% 5Y CAGR

Risk

Low risk

D/E 0.00

Momentum

Strong

85% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹9,145

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹2.45L Cr

52W High / Low

₹9740 / ₹5648

Dividend Yield

0.32%

Promoter Holding

51.88%

EPS (TTM)

₹96.75

Book Value

₹632.49

Key highlights

Low leverage — D/E 0.00
Profitable in all of the last 5 years
Healthy net margin (24%)
Valuation is weak (0.0/10)
Expensive at 95× earnings

4 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Divi's Laboratories Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Divi's Laboratories Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited Max Healthcare Institute Limited

Compare Divi's Laboratories Limited with peers

Divi's Laboratories Limited vs Sun Pharmaceutical Industries Limited Divi's Laboratories Limited vs Torrent Pharmaceuticals Limited Divi's Laboratories Limited vs Apollo Hospitals Enterprise Limited Divi's Laboratories Limited vs Zydus Lifesciences Limited Divi's Laboratories Limited vs Laurus Labs Limited Divi's Laboratories Limited vs Cipla Limited

Related tools & concepts

Value Divi's Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

DIVISLAB newsLatest coverage & filings Open screenerFilter the whole market